Evoked Retinal Response
NCT01415453 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1
Last updated 2013-04-05
Summary
Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, people experience progressive vision loss. There is no known cure for retinitis pigmentosa. The investigators have observed that short pulses of focused ultrasound can cause perception of light when directed to spots on the retinal surface. The investigators propose to conduct a study to determine if pulsed ultrasound will stimulate the perception of light in the absence of functional photoreceptors in people with RP
Conditions
Interventions
- PROCEDURE
-
Ultrasound Stimulus
Short pulses of focused ultrasound will be directed at spots on the retinal surface.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Ronald H Silverman, PhD · Columbia University
Study Design
- Allocation
- NA
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-07-31
- Primary Completion
- 2012-06-30
- Completion
- 2012-06-30
Countries
- United States
Study Locations
More Related Trials
-
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation
NCT00457145 ·Status: COMPLETED ·Phase: PHASE1
-
The FIGHT-RP1 Study
NCT03063021 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate
NCT01314417 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma
NCT00459849 ·Status: UNKNOWN ·Phase: NA
-
PRP vs Bevacizumab for PDR Treatment
NCT02705274 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation
NCT00457067 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis
NCT01327664 ·Status: WITHDRAWN ·Phase: PHASE3
-
Macular Photocoagulation Study (MPS)
NCT00000158 ·Status: UNKNOWN ·Phase: PHASE3
-
Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease
NCT00841373 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Photodynamic and Pharmacologic Treatment of CNV
NCT00570193 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)
NCT00211354 ·Status: WITHDRAWN ·Phase: PHASE2
-
Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).
NCT00211328 ·Status: COMPLETED ·Phase: PHASE2
-
Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)
NCT06852768 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
NCT00469352 ·Status: COMPLETED ·Phase: PHASE3
-
Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
NCT00378196 ·Status: COMPLETED ·Phase: PHASE1
-
Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.
NCT01941329 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments
NCT00976222 ·Status: COMPLETED ·Phase: PHASE4
-
Microbiome as a ThErapeutic Response Biomarker
NCT04721743 ·Status: WITHDRAWN
-
Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity
NCT02134457 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia
NCT02610582 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT01786395 ·Status: TERMINATED ·Phase: PHASE3
-
Refractive Error and Biometry in Retinopathy of Prematurity
NCT03334513 ·Status: COMPLETED
-
Intravitreal Ranibizumab in Recurrent ROP
NCT04539106 ·Status: COMPLETED
-
Use of Thalidomide in Chronic Uveitis
NCT00314665 ·Status: TERMINATED ·Phase: PHASE4
-
Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity
NCT05701124 ·Status: COMPLETED ·Phase: PHASE3